E
MRNS

Ergoteles’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Ergoteles’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-150,334
Closed -$1M – 2009
2022
Q3 		$1M Sell
150,334
-44,954
-23% -$277K 0.04% 482
2022
Q2 		$945K Buy
+195,288
New +$1.19M 0.03% 566

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Ergoteles's MRNS Position: Q4 2022 in Review

Ergoteles sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2022, closing a stake of 150,334 shares — an estimated $1M sold.

Ergoteles first reported a position in MRNS in Q2 2022 and held it in 2 quarters. The position peaked at $1M in Q3 2022. 74 funds tracked by Wall St. Rank hold MRNS as of Q4 2022.

  • Ergoteles reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 150,334 Marinus Pharmaceuticals, Inc shares in Q4 2022, an estimated $1M.
  • Ergoteles first reported a position in Marinus Pharmaceuticals, Inc in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Marinus Pharmaceuticals, Inc position peaked at $1M in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.